Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | PDE4A | P27815 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1129672 | 1.00 | LMNA (0.58) | LMNAL3MBTL1TDP1USP2SLCO1B1 | |
| SCHEMBL1671960 | 1.00 | LMNA (0.58) | LMNAL3MBTL1TDP1USP2SLCO1B1 | |
| Mannitol SCHEMBL4971188 | 1.00 | LMNA (0.58) | LMNAL3MBTL1TDP1USP2SLCO1B1 | |
| SCHEMBL6542053 | 0.97 | TDP1 (0.60) | LMNAL3MBTL1TDP1USP2SLCO1B1 | |
| SCHEMBL11423256 | 0.97 | TDP1 (0.60) | LMNAL3MBTL1TDP1USP2SLCO1B1 | |
| SCHEMBL8075862 | 0.97 | TDP1 (0.60) | LMNAL3MBTL1TDP1USP2SLCO1B1 | |
| SCHEMBL6541711 | 0.95 | LMNA (0.50) | LMNAL3MBTL1TDP1USP2SLCO1B1 | |
| SCHEMBL15892815 | 0.93 | LMNA (0.50) | LMNAL3MBTL1TDP1USP2SLCO1B1 | |
| SCHEMBL14654998 | 0.89 | LMNA (0.37) | LMNAL3MBTL1TDP1 | |
| Succinic Acid SCHEMBL5075718 | 0.85 | USP2 (0.47) | LMNAL3MBTL1TDP1USP2SLCO1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9907854-B2 | Crosslinking reagents, macromolecules, therapeutic bioconjugates, and synthetic methods thereof | CellMosaic, Inc. (US) | 2018-03-06 | — | — | US | disclosed |
| US-9907854-B2 | Crosslinking reagents, macromolecules, therapeutic bioconjugates, and synthetic methods thereof | CellMosaic, Inc. (US) | 2018-03-06 | — | — | US | disclosed |
| US-20170065726-A1 | NOVEL CROSSLINKING REAGENTS, MACROMOLECULES, THERAPEUTIC BIOCONJUGATES, AND SYNTHETIC METHODS THEREOF | CELLMOSAIC INC (US) | 2017-03-09 | — | — | US | disclosed |
| US-20170065726-A1 | NOVEL CROSSLINKING REAGENTS, MACROMOLECULES, THERAPEUTIC BIOCONJUGATES, AND SYNTHETIC METHODS THEREOF | CELLMOSAIC INC (US) | 2017-03-09 | — | — | US | disclosed |
| US-9511150-B2 | Crosslinking reagents, macromolecules, therapeutic bioconjugates, and synthetic methods thereof | CellMosaic, Inc. (US) | 2016-12-06 | — | — | US | disclosed |
| US-8907079-B2 | Crosslinking reagents, macromolecules, therapeutic conjugates, and synthetic methods thereof | CELLMOSAIC INC. (US) | 2014-12-09 | — | — | US | disclosed |
| US-20140206903-A1 | NOVELCROSSLINKING REAGENTS, MACROMOLECULES, THERAPEUTIC CONJUGATES, AND SYNTHETIC METHODS THEREOF | CELLMOSAIC INC (US) | 2014-07-24 | — | — | US | disclosed |
| CN-103476932-A | Nucleic acid modulators of CLEC-2 | REGADO BIOSCIENCES INC | 2013-12-25 | — | — | CN | disclosed |
| WO-2008141799-A1 | OLIGOPHOSPHORAMIDATES | ROCHE DIAGNOSTICS GMBH (DE) | 2008-11-27 | — | — | WO | disclosed |
| US-6274115-B1 | PROVIDING MICELLULAR PARTICLES COMPRISING PHOSPHOLIPID MOLECULES WHICH ARE STABLE TO LEAKAGE IN VITRO AND IN VIVO; MODIFYING MICELLULAR PARTILCES; INTRODUCING INTO BLOOD STREAM; INCORPORATINGAGENT FOR DIAGNOSIS OR THERAPY INTO SECND GROUP | GILEAD SCIENCES, INC. | 2001-08-14 | — | — | US | disclosed |
| US-5441745-A | Marking tumors in the body; biodegradable | VESTAR, INC. (US) | 1995-08-15 | — | — | US | disclosed |
| US-5435989-A | Tumors, phospholipid micelles | VESTAR, INC. (US) | 1995-07-25 | — | — | US | disclosed |
| EP-0182131-B1 | THE USE OF MICELLULAR PARTICLE FOR MAKING COMPOSITIONS FOR TARGETING TUMORS IN HUMANS | VESTAR, INC. (US) | 1991-12-18 | — | — | EP | disclosed |
| EP-0179444-B1 | USE OF A MICELLULAR PARTICLE COMPOSITION ENCAPSULATING A CHEMOTHERAPEUTIC AGENT FOR INTRAVENOUS TARGETING TO TUMORS | VESTAR, INC. (US) | 1991-06-12 | — | — | EP | disclosed |
| US-5019369-A | Method of targeting tumors in humans | VESTAR, INC. (US) | 1991-05-28 | — | — | US | disclosed |
| EP-0182131-A1 | The use of micellular particle for making compositions for targeting tumors in humans | VESTAR, INC. (US) | 1986-05-28 | — | — | EP | disclosed |
| EP-0179444-A2 | Use of a micellular particle composition encapsulating a chemotherapeutic agent for intravenous targeting to tumors | VESTAR, INC. (US) | 1986-04-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170065726-A1 | NOVEL CROSSLINKING REAGENTS, MACROMOLECULES, THERAPEUTIC BIOCONJUGATES, AND SYNTHETIC METHODS THEREOF | CD44, ADH1C, EPCAM | LMNA 4262/4885L3MBTL1 2520/4885TDP1 4207/4885 |
| US-20140206903-A1 | NOVELCROSSLINKING REAGENTS, MACROMOLECULES, THERAPEUTIC CONJUGATES, AND SYNTHETIC METHODS THEREOF | CD44, ADH1C, EPCAM | LMNA 4454/4885L3MBTL1 2862/4885TDP1 4314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.